



- 1 • the clinical criteria for moving people who have migraines with or without  
2 aura between, or off, conventional prophylactic medicines (antiseizure  
3 medicines, antidepressants and antihypertensives), calcitonin gene-related  
4 peptide (CGRP) inhibitor medicines and botulinum toxin type A.

5 This guideline update will focus on prophylactic treatment of migraine with or  
6 without aura in adults and young people aged 12 and over. This may lead to  
7 an update of recommendations 1.3.17 to 1.3.29 in the sections on  
8 prophylactic treatment and prophylactic treatment review, or the development  
9 of new recommendations. Recommendations that are being retained from the  
10 current guideline may be revised to update language, reflect current policy or  
11 practice, and to ensure consistency with new content.

12 This guideline update will not cover:

- 13 • assessment
- 14 • diagnosis
- 15 • acute pharmacological management
- 16 • characteristics of headaches that may be related to serious underlying  
17 disease and need specific investigations and management
- 18 • management of primary headaches other than for migraines with or without  
19 aura
- 20 • non-pharmacological treatments
- 21 • investigation and management of secondary headaches
- 22 • management of comorbidities.

## 23 **Draft review questions**

24 We have developed the following draft review questions. These may change  
25 during guideline development, but the areas covered will remain as listed in  
26 the final scope.

27 The areas covered and draft questions will be used to develop a more  
28 detailed review protocol (if evidence is available).

1 **Pharmacological prophylaxis of migraine with or without aura**

2 A systematic review of the evidence will be conducted to address the  
3 following question:

- 4 1. What is the clinical and cost effectiveness of candesartan for migraine  
5 prophylaxis in people with episodic or chronic migraine (with or without  
6 aura)?

7 The committee’s knowledge, experience and consideration of the evidence  
8 that informed relevant NICE technology appraisals will be used to address the  
9 following question:

- 10 2. What are the clinical criteria for moving people with migraine with or  
11 without aura between, or off, conventional prophylactic migraine  
12 medicines, CGRP inhibitors and botulinum toxin treatments (to include  
13 switching and stopping, and use in combination)?

14 **Economic aspects**

15 We will take economics into account when making recommendations for key  
16 areas in the scope.

17 **NICE quality standards that may be affected by this**  
18 **update**

19 [Headaches in over 12s](#) (2013). NICE quality standard QS42

20 **Incorporating NICE technology appraisals**

21 NICE technology appraisal guidance will be incorporated into the guideline  
22 where relevant. For further details, see our [web page on bringing our](#)  
23 [guidance together by topic](#).

24 NICE’s current technology appraisals for migraine are:

- 25 • [Atogepant for treating migraine](#) (2026). NICE technology appraisal  
26 guidance 1172

- 1 • [Atogepant for preventing migraine](#) (2024). NICE technology appraisal  
2 guidance 973
- 3 • [Rimegepant for treating migraine](#) (2023). NICE technology appraisal  
4 guidance 919
- 5 • [Rimegepant for preventing migraine](#) (2023). NICE technology appraisal  
6 guidance 906
- 7 • [Eptinezumab for preventing migraine](#) (2023). NICE technology appraisal  
8 guidance 871
- 9 • [Fremanezumab for preventing migraine](#) (2022). NICE technology appraisal  
10 guidance 764
- 11 • [Erenumab for preventing migraine](#) (2021). NICE technology appraisal  
12 guidance 682
- 13 • [Galcanezumab for preventing migraine](#) (2020). NICE technology appraisal  
14 guidance 659
- 15 • [Botulinum toxin type A for the prevention of headaches in adults with](#)  
16 [chronic migraine](#) (2012). NICE technology appraisal guidance 260

## 17 **Further information**

The guideline update is expected to be published in February 2027.

To follow the progress of the update, see the [guideline in development page](#).

Our website has information about [how NICE guidelines are developed](#).

18

19 NICE guidelines cover health and care in England. Decisions on how they  
20 apply in other UK countries are made by ministers in the [Welsh Government](#),  
21 [Scottish Government](#) and [Northern Ireland Executive](#).

22 © NICE 2026. All rights reserved. Subject to [Notice of rights](#).